Detalhe da pesquisa
1.
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024.
J Natl Compr Canc Netw
; 22(1): 4-16, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38394781
2.
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial.
Lancet
; 400(10358): 1103-1116, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36099926
3.
Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma.
Oncologist
; 28(2): 157-164, 2023 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36200791
4.
Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer.
Oncologist
; 28(7): 642-e561, 2023 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37134294
5.
The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: A Real-World Multi-Institutional Analysis.
J Urol
; 208(1): 71-79, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35212574
6.
Safety of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer and malignant ureteric obstruction.
BJU Int
; 129(3): 364-372, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33780097
7.
The past, present, and future of pT0 in bladder cancer clinical trials.
Curr Opin Urol
; 32(5): 495-499, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35855573
8.
Cystoscopy and Systematic Bladder Tissue Sampling in Predicting pT0 Bladder Cancer: A Prospective Trial.
J Urol
; 205(6): 1605-1611, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33535799
9.
Sporadic Angiomyolipomas Growth Kinetics While on Everolimus: Results of a Phase II Trial.
J Urol
; 204(3): 531-537, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32250730
10.
Efficacy of Split Schedule Versus Conventional Schedule Neoadjuvant Cisplatin-Based Chemotherapy for Muscle-Invasive Bladder Cancer.
Oncologist
; 24(5): 688-690, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30728277
11.
Update on perioperative systemic therapy for urothelial carcinoma.
Clin Adv Hematol Oncol
; 17(3): 176-183, 2019 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-30969956
12.
Impact of tumor microenvironment composition on therapeutic responses and clinical outcomes in cancer.
Future Oncol
; 14(14): 1409-1421, 2018 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-29848096
13.
Evolving landscape of the treatment of metastatic clear cell renal cell carcinoma.
Clin Adv Hematol Oncol
; 16(10): 677-686, 2018 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-30543598
14.
Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors.
Oncologist
; 22(10): 1232-1237, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28652280
15.
Integrating Immunotherapy Into the Management of Renal Cell Carcinoma.
J Natl Compr Canc Netw
; 15(6): 841-847, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28596263
16.
Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
Curr Treat Options Oncol
; 18(1): 7, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28210995
17.
Systemic therapy for bladder cancer finally comes into a new age.
Future Oncol
; 12(19): 2227-42, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-27402371
18.
19.
Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.
Invest New Drugs
; 33(5): 1040-7, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26091915
20.
Full Spectrum: Efficacy and Toxicity of Immunotherapy in Metastatic Melanoma
J Natl Compr Canc Netw
; 12(12 Suppl 2): S1-S5, 2014 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31094496